Investors focused on the Medical space have likely heard of Molina Healthcare (MOH), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of MOH and the rest of the Medical group's stocks.
Molina Healthcare is one of 833 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. MOH is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for MOH's full-year earnings has moved 10.82% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, MOH has gained about 19.94% so far this year. Meanwhile, the Medical sector has returned an average of 10.05% on a year-to-date basis. This means that Molina Healthcare is performing better than its sector in terms of year-to-date returns.
Looking more specifically, MOH belongs to the Medical - HMOs industry, which includes 11 individual stocks and currently sits at #26 in the Zacks Industry Rank. On average, stocks in this group have gained 3.90% this year, meaning that MOH is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track MOH. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Molina Healthcare, Inc (MOH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research